Abbott LaboratoriesABTEarnings & Financial Report
Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices.
ABT Q4 FY2025 Key Financial Metrics
Revenue
$11.5B
Gross Profit
$6.5B
Operating Profit
$2.3B
Net Profit
$1.8B
Gross Margin
57.0%
Operating Margin
19.6%
Net Margin
15.5%
YoY Growth
4.4%
EPS
$1.01
Abbott Laboratories Q4 FY2025 Financial Summary
Abbott Laboratories reported revenue of $11.5B (up 4.4% YoY) for Q4 FY2025, with a net profit of $1.8B (down 80.8% YoY) (15.5% margin). Cost of goods sold was $4.9B, operating expenses totaled $4.3B.
Key Financial Metrics
| Total Revenue | $11.5B |
|---|---|
| Net Profit | $1.8B |
| Gross Margin | 57.0% |
| Operating Margin | 19.6% |
| Report Period | Q4 FY2025 |
Abbott Laboratories Annual Revenue by Year
Abbott Laboratories annual revenue history includes year-by-year totals (for example, 2025 revenue was $44.3B).
Abbott Laboratories Quarterly Revenue & Net Profit History
Abbott Laboratories results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $11.5B | +4.4% | $1.8B | 15.5% |
| Q3 FY2025 | $11.4B | +6.9% | $1.6B | 14.5% |
| Q2 FY2025 | $11.1B | +7.4% | $1.8B | 16.0% |
| Q1 FY2025 | $10.4B | +4.0% | $1.3B | 12.8% |
| Q4 FY2024 | $11.0B | +7.2% | $9.2B | 84.1% |
| Q3 FY2024 | $10.6B | +4.9% | $1.6B | 15.5% |
| Q2 FY2024 | $10.4B | +4.0% | $1.3B | 12.5% |
| Q1 FY2024 | $10.0B | +2.2% | $1.2B | 12.3% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.96B | $10.38B | $10.63B | $10.97B | $10.36B | $11.14B | $11.37B | $11.46B |
| YoY Growth | 2.2% | 4.0% | 4.9% | 7.2% | 4.0% | 7.4% | 6.9% | 4.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $72.47B | $73.02B | $74.36B | $81.41B | $81.45B | $84.00B | $84.18B | $86.71B |
| Liabilities | $33.66B | $33.70B | $34.56B | $33.75B | $32.64B | $33.43B | $33.23B | $34.58B |
| Equity | $38.81B | $39.32B | $39.80B | $47.66B | $48.81B | $50.56B | $50.95B | $52.13B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $1.02B | $1.96B | $2.71B | $2.87B | $1.42B | $2.05B | $2.79B | $3.31B |